All In Biotech

Drug Trial Radar · NCT02309762

A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of FB825 in Healthy Volunteers

A Phase 1, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single-Ascending Intravenous Doses of FB825

Last checked: Nov 19, 2026Latest source record: Feb 4, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

54

Actual

Start

Mar 2015

Primary completion

Feb 2016

Study completion Feb 2016

Sponsor

Lead sponsor
Fountain Biopharma Inc.Industry
Sponsor type
Industry
First posted
Dec 5, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and immunogenicity of single-ascending IV doses of FB825

Conditions

  • Healthy

Interventions

  • FB825Drug

    FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection

  • PlaceboDrug

    Solution containing no active ingredients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Adverse events (AE)Time frame: Up to day140
  2. Clinical laboratory test results (hematology, coagulation, serum chemistry[including liver function tests], and urinalysis)Time frame: Up to day140
  3. Vital sign measurements (systolic and diastolic blood pressures, heart rate, respiratory rate, and oral body temperature)Time frame: Up to day140
  4. 12-lead ECG resultsTime frame: Up to day140
  5. Physical examination findingsTime frame: Up to day140

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.